ReviewNeuroRx : the journal of the American Society for Experimental NeuroTherapeutics2004
Using advances in neuroimaging to detect, understand, and monitor disease progression in Huntington's disease.
Review in NeuroRx : the journal of the American Society for Experimental NeuroTherapeutics, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 83 citations in OpenAlex.
- Computational Approaches to Neurological Disorder Diagnosis: An In-Depth Review of Current Methods and Future ProspectsCurrent medical imaging · 2026Review
- How is Big Data reshaping preclinical aging research?Lab animal · 2023Review
- Assistive Technology for Cognition and Health-related Quality of Life in Huntington's Disease.Journal of Huntington's disease · 2016Article
- BDNF-TrkB signaling in striatopallidal neurons controls inhibition of locomotor behavior.Nature communications · 2013Article
- Tissue transglutaminase overexpression does not modify the disease phenotype of the R6/2 mouse model of Huntington's disease.Experimental neurology · 2012Article
- Monitoring Huntington's disease progression through preclinical and early stages.Neurodegenerative disease management · 2012Article
- Article
- Pathophysiology of Huntington's disease: time-dependent alterations in synaptic and receptor function.Neuroscience · 2011Review
- Music perception and movement deterioration in Huntington's disease.PLoS currents · 2011Article
- Fully automated atlas-based MR imaging volumetry in Huntington disease, compared with manual volumetry.AJNR. American journal of neuroradiology · 2011Article
- Review
- Brain networks in Huntington disease.The Journal of clinical investigation · 2011Review
- An MRI-based atlas and database of the developing mouse brain.NeuroImage · 2011Article
- Cortical dysfunction in patients with Huntington's disease during working memory performance.Human brain mapping · 2009Article
- [Functional imaging of cognitive processes in Huntington's disease and its presymptomatic mutation carriers].Der Nervenarzt · 2008Review
- Functional abnormalities of the medial temporal lobe memory system in mild cognitive impairment and Alzheimer's disease: insights from functional MRI studies.Neuropsychologia · 2008Review
- Article
- Thalamic metabolism and symptom onset in preclinical Huntington's disease.Brain : a journal of neurology · 2007Article
- Advances in functional magnetic resonance imaging: technology and clinical applications.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2007Review
- Voxel-based morphometry indicates relative preservation of the limbic prefrontal cortex in early Huntington disease.Journal of neural transmission (Vienna, Austria : 1996) · 2007Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Transgenic mouse models and other screens are being used to identify potential therapeutic agents for use in clinical trials in Huntington's disease (HD). The development of surrogate markers that can be used in clinical therapeutics is an active area of research. Because HD is relatively uncommon and only a portion of available subjects meet inclusion and exclusion criteria, therapeutic trials are limited by the availability of potential subjects as well as the relative insensitivity of the clinical measures used. Neuroimaging methods offer the potential to provide noninvasive, reproducible, and objective methods not only to better understand the disease process but also to follow in clinical studies to determine if a drug is effective in slowing down disease progression or perhaps even in delaying onset. Following is a review of the literature, which highlights the studies that have been published to date.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.